Reine Escalona

Deep work

Today I’m talking with Rachel Tham, a principal statistician, about a book that has been incredibly impactful in both of our lives—Deep Work. We discuss what deep work is and how it can help statisticians at work.  Deep work is a concept developed by Cal Newport which encourages people to focus intensely on one task …

Deep work Read More »

Single arm studies

Why are companies often running single arm studies in development?  What are the potential drawbacks and why is it not a binary choice between full comparative study and single arm trial? What are solutions in between to find a balance between feasibility and rigour? Single arm studies are a popular method for collecting data despite …

Single arm studies Read More »

3 steps to make your research more reproducible

Reproducible research is a key part of research in the pharma industry. It allows for transparency, understanding, and accuracy in the research process. But how can you make your research more reproducible? Today, I talk with Heidi Seibold who has dedicated her career to helping researchers become more reproducible. Let’s take a look at 3 …

3 steps to make your research more reproducible Read More »

What will be the role of health economics in the future EU HTA?

Are you a statistician working in the pharmaceutical industry and never got in touch with economic modelling and network meta-analyses? Then you should listen to this episode! The EU HTA will not only affect all statisticians in the pharmaceutical industry with respect to skill sets and collaboration (we talked about that in podcast #3), but …

What will be the role of health economics in the future EU HTA? Read More »

Future implications of EU HTA and how Next Gen get involved

All statisticians in the Pharmaceutical Industry will be impacted by the new EU HTA regulation. Activities around HTA submissions will happen earlier than currently, in parallel to the regulatory approval process for marketing authorization. There will be an increased scope of evidence for the joint clinical assessment to fulfill the needs of all EU member …

Future implications of EU HTA and how Next Gen get involved Read More »

The recent Alzheimer story – an absolute low for the industry and especially for statisticians

End of last year, a congressional report about the approval of an Alzheimer drug by the FDA was published. It critiques both the FDA and the sponsor company Biogen. Reuters and many other major news organisations reported about it. Today, I interviewed Anja Schiel about this topic. We talked about the background of Alzheimer and …

The recent Alzheimer story – an absolute low for the industry and especially for statisticians Read More »